Assessing the clinical progress of the bispecific nanobody sonelokimab

INTRODUCTION: Sonelokimab, a bispecific nanobody targeting interleukins (IL)-17A and IL-17F, has emerged as a novel therapeutic candidate for chronic inflammatory diseases, such as psoriasis, hidradenitis suppurativa (HS), and psoriatic arthritis. Its innovative design offers improved tissue penetration, rapid clearance, and reduced immunogenicity, addressing limitations of current monoclonal antibody therapies. AREAS COVERED: This review evaluates the pharmacodynamics, pharmacokinetics, clinical efficacy, and safety profile of sonelokimab, drawing from data obtained in phase 1 and 2 trials. Key findings highlight its superior performance in disease-specific indices such as the Psoriasis Area and Severity Index (PASI) and Hidradenitis Suppurativa Clinical Response (HiSCR). A favorable safety profile with common adverse effects like nasopharyngitis, pruritus, headache have been reported. EXPERT OPINION: Sonelokimab's dual inhibition of IL-17A and IL-17F provides enhanced efficacy over single-target therapies. Its nanobody-based structure enables deeper tissue penetration and better disease control. Further phase 3 trials and head-to-head studies are crucial to establish its long-term efficacy and safety, potentially positioning it as a leading therapeutic option.